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Abstract. It is estimated that breast cancer will be the second
leading cause of cancer‑associated mortality in women in 2018.
Previous research has demonstrated that the atypical protein
kinase C‑ζ (PKC‑ζ) is a component of numerous dysregulated
pathways in breast cancer, including cellular proliferation,
survival, and cell cycle upregulation. The present study investigated the PKC‑ζ protein in breast tissue to evaluate its potential
as a biomarker for breast cancer invasion, and demonstrated
that an overexpression of PKC‑ζ protein can be indicative of
carcinogenesis. The present study analyzed the expression of
PKC‑ζ in individuals with no tumor complications and malignant female human breast tissue samples (lobular carcinoma
in situ, invasive lobular carcinoma, ductal carcinoma in situ
and invasive ductal carcinoma) with the use of western blot
analysis, immunohistochemistry and statistical analysis
(83 samples). The present study also evaluated the invasive
behavior of MDA‑MB‑231 breast cancer cells following the
knockdown of PKC‑ζ with a Transwell invasion assay and an
immunofluorescent probe for filamentous actin (F‑actin) organization. The data demonstrated that PKC‑ζ expression was
identified to be higher in invading tissues when compared with
non‑invading tissues. The results also suggest that PKC‑ζ is
more abundant in ductal tissues when compared with lobular
tissues. In addition, the protein studies also suggest that PKC‑ζ
is a component for invasive behavior through the Ras‑related
C3 botulinum toxin substrate 1 (Rac1) and Ras homolog gene
family member A (RhoA) pathway, and PKC‑ζ is required for
the F‑actin reorganization in invasive cells. Therefore, PKC‑ζ
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should be considered to be a biomarker in the development of
breast cancer as well as an indicator of invading tumor cells.
Introduction
In the current research, cancer statistics show that invasive
breast cancer is projected to have 234,190 new cases and
deaths, for which 231,840 will be women (1). Approximately
40,290 women will die from invasive breast cancer in 2018 (2).
Although the percentage of mortalities has decreased over the
last few years, breast cancer still ranks as the second leading
cause of cancer death in women; treatments usually entail
invasive surgeries, including breast‑conserving surgeries and
mastectomies (1). From a clinical standpoint, invasive ductal
carcinoma (IDC) is the most common form of breast cancer,
affecting 50‑75% of breast cancer diagnoses (2). Breast cancer
is a heterogeneous disease, and research has shown that the
top mutated genes in breast carcinomas and carcinomas in situ
are Phosphatidylinositol‑4,5‑Bisphosphate 3‑Kinase Catalytic
Subunitα (PIK3CA), Tumor Protein P53 (TP53), and E‑cadherin
(CDH1) (3). However, this investigation shows a link between
protein kinase C‑ζ (PKC‑ζ) protein overexpression and breast
cancer development, particularly in invasive behavior. For this
reason, breast cancer biomarkers are of interest, as they may
help to predict breast cancer incidents and contribute to better
therapeutic regimens.
The complete understanding of histological and pathological features of the lobular and ductal carcinomas are far
from full elucidation. In an investigation by Ruibal et al, the
authors concluded that, in the absence of the axillary node,
lobular carcinomas had a higher concentration of breast cancer
estrogen‑inducible protein (pS2) than ductal carcinomas (4).
Lobular carcinomas were also shown to have a higher
frequency of diploidy, which suggests that lobular carcinomas
are less aggressive and grow slower (4).
An overexpression of PKC‑ζ protein promotes carcinogenesis
by stimulating cancer cell proliferation through pathways such
as the Nuclear factor‑κB (NF‑κB), which plays an essential role
in cancer initiation and progression (5). Previous studies suggest
that PKC‑ζ is a regulatory factor for the nuclear translocation of
NF‑κB that in turn represses E‑cadherin (6,7). Although the link
between the loss of E‑cadherin and cancer prognosis remains
ambiguous, recent findings showed that E‑cadherin possesses
a vital tumor suppressive role (8). Moreover, some researchers
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have paralleled PKC‑ζ to the phosphorylation of the Inhibitor
of κB kinase (IKK) complex, which in turn phosphorylates the
Inhibitor of κ B (Iκ B) and triggers Iκ B degradation (7,9). The
degradation of Iκ B releases NF‑κ B, allowing its translocation
from the cytosol into the nucleus, where it functions as a transcription factor (9). The transcription factor applies explicitly to
targets such as apoptosis regulators and stress response genes.
Furthermore, studies show that NF‑κB also plays a role in epithelial to mesenchymal transition, a crucial carcinogenic event (7).
PKC‑ζ has also been linked to metastatic behaviors of
cancer cells. In a study by Islam et al, the Ras‑related C3
botulinum toxin substrate 1 (Rac1)/Pak1/β‑Catenin signaling
cascade in colorectal cancer cell lines was evaluated after the
inhibition of PKC‑ζ (10). The knockdown of PKC‑ζ decreased
the nuclear translocation of β‑Catenin which ultimately leads
to reduced colorectal cell proliferation and metastasis (10).
These data were further supported by another investigation
performed by Wu et al, which determined that inhibition of
PKC‑ζ in breast cancer cell lines decreased adhesion and actin
polymerization (11). These studies advocate the theory that
PKC‑ζ as a critical component of the invasive behaviors of
cancer cells.
Although PKC‑ ζ has been studied in invasive breast
cancers (most commonly ductal), there have been no examinations of PKC‑ζ expression in other types of breast cancer
(such as carcinomas in situ). An investigation by Lin et al
confirmed that atypical PKC isoforms were elevated in breast
cancer tissues (IDC, specifically) when compared to adjacent healthy breast tissue (12). Additionally, Schöndorf et al
determined that antineoplastic agents affect the activation
of PKC in IDC breast cancer tumors (13). In this study,
our focus was to further investigate the PKC‑ζ expression
profile in the four histological subtypes of breast cancer
such as lobular carcinoma in situ (LCIS), invasive lobular
carcinoma (ILC), ductal carcinoma in situ (DCIS) and IDC.
We also evaluated the difference in the PKC‑ζ expression
among healthy, invasive and non‑invasive tissues. Moreover,
the invasive characteristics of MDA‑MB‑231 breast cancer
cells were examined upon the inhibition of PKC‑ζ. We found
that PKC‑ζ is overexpressed in IDC and ILC tissue specimens compared to other subtypes. In addition, the inhibition
of PKC‑ζ decreased the invasion of MDA‑MB‑231 breast
cancer cells.
Materials and methods
Specimen collection and tissue f ractionation. The
NCI‑supported Cooperative Human Tissue Network
(CHTN; Birmingham, AL, USA) collected and provided
the breast tissue samples (normal, LCIS, ILC, DCIS, and
IDC). The specimens were collected and snap‑frozen in
liquid nitrogen or placed in dry ice and stored in a liquid
nitrogen vapor phase freezer (‑196˚C), where the tissues
stayed until shipment. The tissues were shipped in dry ice.
Formalin‑fixed paraffin‑embedded tissues (FFPE) were
also provided for immunohistochemistry staining. Tissues
were selected based on their histological features (normal,
LCIS, ILC, DCIS, and IDC). The mean age of patient
samples collected was 51 years and the collection period of
the samples was 2001‑2015. Normal tissues were selected

from breast reduction patients with no previous diagnosis of
cancer or the area adjacent to a patient's malignant tumors.
Patients with DCIS and LCIS were selected based on the
lack of invasive tissue adjacent to the extraction site; some
tissues were taken from patients with invasive tissues in the
opposite breast.
The tissue specimens were then resuspended and sonicated
for 3x5 sec cycles on ice in 1 ml of homogenization buffer
(Pierce® Immuno Precipitation Lysis Buffer, 25 mM Tris‑HCl
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP‑40 and 5% glycerol;
Thermo Fisher Scientific, Inc., Waltham, MA, USA), followed
by, centrifugation at 12,879 x g for 15 min at 4˚C to obtain
cell extracts. Subsequently, 250 µl of albumin removal resin
(Pierce™ Albumin Depletion kit; Thermo Fisher Scientific,
Inc.) was added to the lysate and left at 4˚C overnight. The
samples were further centrifuged at 12,879 x g for 15 min at
4˚C, the supernatant was subsequently collected, and protein
content was measured according to Pierce® 660 nm Protein
Assay reagent protocol (Thermo Fisher Scientific, Inc.) and
NanoDrop 2000 (Thermo Fisher Scientific, Inc., Wilmington,
DE, USA).
Cell culture. The metastatic breast cancer cell line,
MDA‑MB‑231 was obtained from American Type Tissue
Culture Collection (ATCC; Manassas, VA, USA). The
MDA‑MB‑231 cells were sub‑cultured and maintained in
T75 flasks containing Dulbecco's modified Eagle's media
(DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham,
MA, USA), supplemented with 10% fetal bovine serum (FBS)
and 1% antibiotics (penicillin 10 U/ml and streptomycin
10 mg/ml). Cells were incubated at 37˚C and 5% CO2. Cells
were used at 70‑80% confluency for the experiments.
Western blot analysis. Like tissue lysates, MDA‑MB‑231
cell extracts were also prepared after the addition of cell
lysis buffer, sonication, and centrifugation (at 12,879 x g for
15 min at 4˚C). For western blot analysis, an equal amount
(20‑30 µg) of protein from tissue and cell lysates were
loaded in 10% polyacrylamide gels and separated by using
sodium dodecyl sulfate‑polyacrylamide gel electrophoresis
(SDS‑PAGE). The proteins were then transblotted onto a
0.4 µM nitrocellulose membrane. Subsequently, the membranes
were incubated with 5% milk blocking solution, followed by,
primary solution of anti‑PKC‑ζ (SC‑17781; 1:1,000; Santa Cruz
Biotechnology, Dallas, TX, USA; and 9372s; 1:1,000; Cell
Signaling Technology, Danvers, MA, USA), anti‑E‑cadherin
(701134; 1:1,000; Invitrogen; Thermo Fisher Scientific, Inc.),
anti‑Ras homolog gene family member A (RhoA; ab54835,
1:4,000; Abcam, Cambridge, UK) and anti‑Rac1 (4651s;
1:1,000; Cell Signaling Technology) in 5% bovine serum
albumin (BSA). Finally, the membranes were incubated
with secondary antibodies. All the secondary antibodies
(anti‑rabbit and anti‑mouse) were obtained from Bio‑Rad
Laboratories, Hercules, CA, USA (cat. no. 170‑6515 and cat.
no. 170‑6516; 1:2,000). The immunoreactive bands were then
visualized by chemiluminescence reaction, according to the
manufacturer's instructions (SuperSignal™ West Pico PLUS
Chemiluminescent Substrate; Thermo Fisher Scientific, Inc.).
A monoclonal antibody to β ‑actin (SC‑1616; Santa Cruz
Biotechnology) was used as a loading control.
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Figure 1. Western blot and immunohistochemistry analysis of PKC‑ζ expression in normal and malignant tissues. Malignant tissues were evaluated for the expression of PKC‑ζ. (A) We ran 20‑30 µg of tissue lysate and probed with a PKC‑ζ antibody. (B) The ratios of PKC‑ζ to β‑actin in healthy tissue and the four subtypes
of malignant breast tissue were derived using the densitometry. The white bar (healthy) represents the control and the error bars represent the standard error. The
standard deviation, a Student's t‑test (P<0.05) and a one‑way ANOVA was used to evaluate the western blot data as well with the post‑hoc Tukey's HSD test (P<0.01),
Scheffé multiple comparison (P<0.05), Bonferroni (P<0.01) and Holm (P<0.01). Statistical tests showed no meaningful relationship between the healthy and LCIS,
or the ILC and DCIS. *, statistically relevant relationship between normal and IDC breast tissue. (C) FFPE samples were probed with PKC‑ζ and stained for immunohistochemistry. The scoring was based on the abundance or lack thereof PKC‑ζ expression: Score: 0, no expression; 1, weak expression; 2, moderate expression;
3, abundant expression; 3 plus (+), strong expression. Image original magnification, x20. LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma; IDC,
invasive ductal carcinoma; DCIS, ductal carcinoma in situ; PKC‑ζ, protein kinase C‑ζ; FFPE, formalin‑fixed paraffin‑embedded tissues.

Densitometry. The densitometry was performed using Image J
(National Institutes of Health, Bethesda, MD, USA) software
by the subtraction of background noise from the density of each
band to derive the corrected intensity. All samples were normalized based on the intensity of β‑actin bands on each blot.
Immunohistochemistry. FFPE tissues received from CHTN
were sent to the Tissue Core, Moffitt Cancer Center (Tampa,
FL, USA). Two different patient tissues were selected for each
subtype (normal, LCIS, ILC, DCIS, and IDC) based on the
criteria mentioned previously, with a total N=10. Briefly, tissues
were stained with haemotoxylin and eosin (H&E), and pathology
quality control (PQC) were performed by a Tissue Core pathologist to confirm breast tissue subtype and diagnosis. The slides
were prepared and stained with antibodies for PKC‑ζ (ab59364;
1:1,000; rabbit polyclonal; Abcam). A uterine carcinoma specimen was selected as a positive control based on antibody data
sheet and the Human Protein Atlas recommendations. Slides
were stained using a Ventana Discovery XT automated system
(Ventana Medical Systems, Tucson, AZ, USA) as per the manufacturer's protocol with proprietary reagents. Briefly, slides were
deparaffinized on the automated system with EZ Prep solution
(Ventana Medical Systems). The heat‑induced antigen retrieval
method (CC1 standard) was used with the PKC‑ζ primary rabbit
antibody (Ventana Medical Systems). This antibody that reacts
to the human isoform of PKC‑ζ was used at a 1:1,000 concentration in Dako antibody diluent (Dako; Agilent Technologies, Inc.,
Santa Clara, CA, USA) and incubated for 32 min. The Ventana
OmniMap Anti‑Rabbit Secondary Antibody (Ventana Medical
Systems) was used for 16 min. The detection system used was
the Ventana ChromoMap kit and slides were then counterstained
with haematoxylin. Slides were subsequently dehydrated and
cover‑slipped as per normal laboratory protocol. The Moffitt

Cancer Center Tissue Core pathologist selected the optimal
condition, titration, and incubation time to be used on the control
and the breast selected slides. Subsequently, the pathologist
evaluated the slides using the combinative semi quantitative
scores (score, 0‑3) (14). Images were taken on a light microscope
Olympus BX51 (Olympus Corp., Tokyo, Japan).
Knockdown of PKC‑ζ for invasion pathway analysis. Human
breast cancer cells MDA‑MB‑231 were grown in 100 mm
plates and transfected with 20 nM of scrambled RNA and
siPRKCZ (5'‑GCAUGAUGACGAG GAUAUUGACUGG ‑3',
SR303747A; Origene, Rockville, MD, USA) for 48 h. Cells
were lysed as previously described and the lysates were run
on western blots.
Cell invasion assay by crystal violet staining of invaded
cells. Cells were serum starved for 24 h, followed by detachment and plating into the upper chamber of a 96‑well 8 µm
Transwell permeable support, coated with 0.5X basement
membrane extract (BME; both Corning Inc., Corning, NY,
USA) for the evaluation of invasion. Serum (10%) containing
media was loaded into the receiver plate (lower chamber) as
a chemoattractant. MDA‑MB‑231 cells at the upper chamber
were transfected with 20 nM siPRKCZ for 24 h. Four experimental treatment groups for the cells were performed: Control
(non‑treated), Si‑Tran (transfection reagent), scrambled siRNA
(random RNA) and siRNA for PRKCZ (for knockdown of
PKC‑ζ protein expression). The cells were treated with the
transfection reagent (Si‑Tran) and universal scrambled RNA
to establish the effect of targeted small interfering RNA
(siPRKCZ) only. The invasive cells that passed into the lower
chamber were then fixed with 4% paraformaldehyde, stained
with 2% crystal violet in 2% ethanol, washed with distilled
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Table I. The selection of breast specimens with pathological characteristics.
LN

Grade/stage

NA
NA
NA
NA
NA
+
+
NA
‑	
+
NA
‑	
‑	
+
NA
+
+
NA
‑	
NA
‑	
+
NA
‑	
NA
NA
NA
‑	
+
+
NA
NA
‑	
+
+
+
+
+
NA
NA
NA
NA
NA
NA
‑	

ER

PR

Histology

NA
NA
NA
Normal
NA
NA
NA
Normal
NA
NA
NA
Normal
NA
NA
NA
Normal
NA
NA
NA
LCIS
II/III	‑	‑	 LCIS
II/III
+
+
LCIS
NA
NA
NA
ILC
II/III
NA
NA
ILC
III/III
+
+
ILC
NA
NA
NA
ILC
I/III
+
+
ILC
NA
NA
NA
ILC
II/III
+
+
ILC
NA
NA
NA
ILC
II/III
+
+
ILC
III/III
+
+
ILC
NA
NA
NA
ILC
NA
+
+
ILC
I/III
+	‑	 ILC
III/III	‑	+
IDC
NA	‑	+
IDC
NA
NA
NA
IDC
I/III
+
+
IDC
III/III
NA
NA
IDC
NA
+	‑	 IDC
NA
+
+
IDC
II/III
NA
NA
IDC
III/III
NA
NA
IDC
III/III
NA
NA
IDC
NA
+	‑	 IDC
NA
NA
NA
IDC
III/III	‑	‑	 IDC
II/I
+
+
IDC
NA	‑	‑	 IDC
NA	‑	 NA
IDC
NA
+
+
IDC
NA
NA
NA
IDC
I/III
NA
NA
IDC
NA	‑	‑	 IDC
NA
+	‑	 IDC
NA
NA
NA
IDC
NA
NA
NA
DCIS
NA
NA
NA
DCIS
NA
NA
NA
DCIS

Race

PKC‑ζ expression

Number of patient samples

Black
NA
White
White
Black
White
White
Black
NA
NA
NA
White
White
White
White
Black
NA
NA
White
White
Black
Black
NA
White
White
White
Black
NA
NA
NA
NA
NA
White
White
White
White
White
White
White
White
White
White
Black
NA
Black

No
No
No
Yes
No
No
Yes
No
No
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes

9
4
15
4
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
1
2
1
1
2
1
1
2
3
1
4
1

Tissue specimen were selected as described in material and methods and further sorted by the presence of PKC‑ζ protein. LN, lymph node; ER,
estrogen receptor; PR, progesterone receptor; PKC‑ζ, protein kinase C‑ζ; LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma;
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; NA, not available.

water and photographs were captured after drying using a light
microscope Motic AE31E.

Phalloidin staining of filamentous actin (F‑actin). Human
breast cancer cells MDA‑MB‑231 (1x104 cells) were grown
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Table II. The status of PKC‑ζ in malignant and healthy breast
tissue.
Tissue type
Normal tissue
LCIS
ILC
DCIS
IDC

Not
present

Weakly
present

Positively
present

29
2
8
5
6

1
1
4
0
5

2
0
1
1
18

Healthy breast tissue was obtained from breast reductions or the area
adjacent to a patient's malignant tumors. Malignant tumors were either
LCIS, ILC, DCIS, or IDC. The expression of PKC‑ζ was evaluated
as not present (ratio 0), weakly present (ratio <0.01) and positively
present (ratio >0.01). LCIS, Lobular carcinoma in situ; ILC, invasive
lobular carcinoma; DCIS, ductal carcinoma in situ; IDC, invasive
ductal carcinoma; PKC‑ζ, protein kinase C‑ζ.

in 2‑well chamber slides, followed by transfection with
20 nM universal scrambled RNA and siPRKCZ for 24 h.
In addition, cells were also evaluated with the transfection
reagent and without any treatment to establish the targeted
effect of PKC‑ζ knockdown. Fixation was performed with
4% paraformaldehyde. F‑actin was subsequently stained with
1X Phalloidin‑iFluor 594 (Abcam) in 1% BSA‑phosphate
buffered saline (PBS) solution for an hour at room temperature. Cells were washed, counterstained with the nuclear
stain 4',6‑diamidino‑2‑phenylindole (DAPI; Invitrogen;
Thermo Fisher Scientific, Inc.) and examined under Nikon
MICROPHOT‑FX fluorescence microscope (Ex/Em=590/618).
Photographs were captured using ProgRes®Capture 2.9.0.1.
Statistical analysis. The statistical significance of the western
blot analysis data was evaluated by a Student's t‑test (normal
N=32; LCIS N=3; ILC N=13; DCIS N=6; IDC N=29; overall
N=83 at P<0.05; standard error represented) and the linear
regression test (N=20; R2 value) with GraphPad software (15).
A one‑way ANOVA was also used to evaluate the western
blot analysis data as well with the post‑hoc Tukey's HSD test
(P<0.01), Scheffé multiple comparison (P<0.05), Bonferroni
(P<0.01) and Holm (P<0.01). The contingency table
Chi‑squared statistical analysis (normal N=32; LCIS N=3; ILC
N=13; DCIS N=6; IDC N=29; overall N=83 at P<0.00001) for
the expression of PKC‑ζ and breast subtype was performed
using the Chi‑Squared Test Calculator from Social Science
Statistics (16). Clinical parameters such as estrogen receptor
expression and Scarff‑Bloom‑Richardson grade (presented
in the pathology reports) were also investigated with this
statistical software (N=25 and N=22, respectively). A one‑way
ANOVA was used to analyze the number of cells invaded after
crystal violet staining (P<0.05).
Results
PKC‑ζ is overexpressed in malignant breast tissues. PKC‑ζ
protein expression was measured in breast samples with no
tumor complication and malignant breast tissue samples by
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western blot analysis. Our investigation showed a correlation
between the overexpression of PKC‑ζ and malignant breast
cancer tissue (Fig. 1A and B; Table III). It was challenging to
obtain DCIS (N=6) and LCIS (N=3) since these tissue types
have lower occurrence rates; hence the results reflect a comparison of the two main subtypes: IDC, N=29, (50‑75% diagnoses)
and ILC, N=13 (10‑15% diagnoses). The westerns represent the
majority of samples. Normal tissue only had 3 of 32 samples
with expression of PKC‑ζ and DCIS only had 1 of 6 samples
with PKC‑ζ present (Table II). Among the IDC subtypes of
malignant breast tissue, >74% of tissue samples overexpressed
PKC‑ζ protein. Less than 5% of healthy breast tissue samples
exhibited PKC‑ ζ protein expression. Although a paired
Student's t‑test (P<0.05) and one‑way ANOVA (P<0.01) showed
no significant correlation between the overexpression of PKC‑ζ
protein in malignant tissue (all four subtypes) and healthy
tissue, it did demonstrate a significant correlation between
healthy breast tissue and IDC (Tukey HSD P‑value 0.0056404,
P<0.01; Scheffé P‑value 0.0121289, P<0.05; Bonferroni and
Holm P‑value 0.0063104, P<0.01) (Fig. 1B). According to
the significance of the contingency table (Table III), there is
an established association between the protein expression of
PKC‑ζ and sample type (P<0.00001). However, the PKC‑ζ
expression could not be statistically linked to the presence of
ER and nuclear grade (Table IV; Fig 3C). These data suggest
that it is unlikely that healthy breast tissue samples overexpress
PKC‑ζ protein. Instead, PKC‑ζ is overexpressed in malignant
breast tissue samples.
PKC‑ ζ protein levels are higher in invading breast cancer
subtypes. To compare the expression of PKC‑ζ in non‑invading
tissues and invading tissues, western blot and immunohistochemistry were performed. Western blot analysis data showed
that PKC‑ ζ protein expression was higher in IDC when
compared to the ILC, LCIS and the DCIS (Fig. 1A and B).
According to immunohistochemistry findings, breast
specimens were scored for the expression of PKC‑ζ by the
pathologist (Fig. 1C). Normal tissue had no to moderate expression (score, 0,2), LCIS had abundant expression (scores, 3,3),
ILC had moderate to strong expression (scores, 2,3+), DCIS
had moderate to abundant expression (scores, 2.3), and IDC
had abundant to strong expression (scores, 3,3+). The most
robust expression was found to be in ILC and IDC represented
by the 3+ score. However, ILC was found to have moderate to
strong expression, whereas IDC was found to have abundant to
strong expression. These findings suggest that PKC‑ζ is found
higher in invading tissues when compared to non‑invading
tissues and more so in IDC when compared to ILC. These data
suggest that the stage between in situ and invading malignancy
can be correlated to an increased PKC‑ζ protein expression.
PKC‑ζ and E‑cadherin levels in tissue specimens. Since the
decreased expression of E‑cadherin is indicative of a more
aggressive phenotype, the relationship between PKC‑ζ and
E‑cadherin protein levels was studied. Western blot analysis
was used in the context of probing for PKC‑ζ and E‑cadherin in
IDC breast tissues (Fig. 2A). We randomly selected 8 samples
out of the 29 IDC tissue specimen to illustrate the data. We
could not establish a significant relationship between PKC‑ζ
expression and E‑cadherin expression in IDC samples. Our
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Table III. Chi‑square statistical analysis results of normal and malignant breast subtypes (normal, LCIS, ILC, DCIS and IDC;
N=83)
Variable
PKC‑ζ present
PKC‑ζ absent
Column totals

Normal
3
29
32

LCIS

ILC

DCIS

IDC

Row totals

1
2
3

5
8
13

1
5
6

23
6
29

33
50
83 (grand total)

Chi‑square

P‑value

32.6715

<0.00001

a

Values were considered to be statistically significant at P<0.01. The Chi‑square analysis compared the absence or presence of PKC‑ζ expression (determined by western blots) in different breast tissue specimens.LCIS, lobular carcinoma in situ; ILC, invasive lobular carcinoma; DCIS,
ductal carcinoma in situ; IDC, invasive ductal carcinoma; PKC‑ζ, protein kinase C‑ζ.

Table IV. Chi‑square statistical analysis results of estrogen receptor expression (N=25).
Variable

ER+

PKC‑ζ present
PKC‑ζ absent
Column totals

10
6
16

ER‑	

Row totals

6
3
9

Chi‑square

16
9
25 (grand total)

0.0434

P‑value
0.834969

Values were considered to be not statistically significant at P<0.10. The Chi‑square analysis compared the absence and presence of PKC‑ζ
expression (determined by western blot) with the absence (-) and presence (+) of estrogen receptors (ER) in different breast tissue specimens.
PKC‑ζ, protein kinase C‑ζ.

Table V. Chi‑square statistical analysis results of Scarff‑Bloom‑Richardson grading (N=22).
Variable

NG1

NG2

NG3

Row totals

PKC‑ζ present
4
4
5
13
					
PKC‑ζ absent
3
2
4
9
Column totals
7
6
9
22 (grand total)

Chi‑square

P‑value

0.2

0.90485

Values were considered to be not statistically significant at P<0.01. The Chi‑square analysis compared the absence and presence of PKC‑ζ
expression (determined by western blot) with nuclear grades 1-3 (NG1-NG3) in different breast tissue specimens. PKC‑ζ, protein kinase C‑ζ.

linear regression test (Fig. 2B) showed no significance (P<0.05)
between the expressions of PKC‑ζ and E‑cadherin protein
levels in 20 randomly selected IDC breast tissue samples. The N
value was too low to take into consideration for LCIS, ILC and
DCIS. Normal breast tissues were not taken into consideration
since the PKC‑ζ expression was only found in 3 samples out
of 32. However, our investigation established the relationship
between E‑cadherin protein expression and nuclear grade
diagnosis (Fig. 2C). The Scarff‑Bloom‑Richardson scale data was
derived from the pathology reports (summarized in Tables I and
V). The results show that E‑cadherin protein expression had an
inverse relationship to nuclear grade diagnosis. Even though the
PRKCZ gene is not one of the top mutated genes in breast cancer
(carcinomas and carcinomas in situ), CDH1 is on the top of the
list (Table VI) (3).
PRKCZ gene silencing decreases the invasion of breast
cells. To investigate the effects of PKC‑ζ inhibition on the

invasive behavior of breast cancer cells, a Transwell invasion
assay and immunostaining of F‑actin were performed. When
compared to the control, PKC‑ζ knockdown decreased the
invasion of breast cancer cells by 60% and was significant
(Student's t‑test P<0.05, one‑way ANOVA Tukey HSD P‑value
0.0029646, P<0.01; Scheffé P‑value 0.0049622, P<0.01;
Bonferroni P‑value 0.0040067, P<0.01 and Holm P‑value
0.0040067, P<0.01) (Fig. 3A and B). In addition, the levels of
two important components of metastatic pathways, Rac1 and
RhoA, were also decreased dramatically (Fig. 3C). Moreover,
MDA‑MB‑231 breast cancer cells were fixed and stained with
phalloidin probe to visualize the impacts of PRKCZ gene
silencing on F‑actin organization. The silencing of PRKCZ
caused the reorganization of F‑actin around the cell cytoskeleton (Fig. 4). Taken together, these data advance the theory
that PKC‑ζ modulates the invasive behavior of breast cancer
cells by the regulation of invasion through the Rac1/RhoA
pathway and cytoskeleton filaments.
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Figure 2. The non‑linear relationship between E‑cadherin expression and PKC‑ζ expression and the E‑cadherin ratio measured by tumor nuclear grade in
IDC. (A) We investigated the expression of PKC‑ζ in comparison to E‑cadherin expression in IDC diagnosed breast tissues by western blot. The western blot
represents 8 samples of IDC. (B) We normalized densities of PKC‑ζ and E‑cadherin protein expression based on β‑actin levels and plotted them on a scattered
plot graph to test for a linear relationship (N=20). (C) The E‑cadherin ratios were further compared to nuclear grade diagnosis listed on the pathology report,
according to the Scarff‑Bloom‑Richardson scale. PKC‑ζ, protein kinase C‑ζ; IDC, invasive ductal carcinoma.

Figure 3. PKC‑ζ knockdown retards invasion of MDA‑MB‑231 breast cancer cells. MDA‑MB‑231 breast cancer cells were placed in the upper chamber of
Transwell plate coated with 0.5X BME and serum containing media was placed in the lower chamber as a chemoattractant. Following transfection with
siPRKCZ and scrambled RNA, cells that invaded through the BME and migrated into the lower chamber were stained with crystal violet and (A) observed
under a microscope at magnification, x10; scale bar, 1 mm. Untreated cells and cells treated with the transfection reagent (Si‑Tran) were also used to establish
the effect on invasion. (B) The cells were counted for each treatment image (N=3), averaged and analyzed with the standard deviation, a Student's t‑test (*P<0.05)
and a one‑way ANOVA was also used to evaluate the data with the post‑hoc Tukey's HSD test (P<0.01), Scheffé multiple comparison (P<0.01), Bonferroni
(P<0.01) and Holm (P<0.01). All statistical tests were used to determine the statistical significance of the invasion data. (C) The cells were further investigated
by western blot to analyze the Rac1/RhoA pathway. This data was quantified and averaged for the graph with standard error of the mean represented. PKC‑ζ,
protein kinase C‑ζ; BME, basement membrane extract; Rac1, Ras‑related C3 botulinum toxin substrate 1; RhoA, Ras homolog gene family member A.

Discussion
Previously, Yin et al showed that the expression of PKC‑ζ
was higher in invading breast tissues compared to samples
uncomplicated with tumors and the highest PKC‑ζ protein
expression existed in stage III human breast ductal carcinomas (17). Likewise, Paul et al concluded that the depletion

of PKC‑ζ reduced the invasive behaviors of MDA‑MB‑231
cells by upregulating epithelial markers such as Zonula
occludens‑1 (ZO‑1) and E‑cadherin (6). They also found that
PKC‑ζ activation (phosphorylated PKC‑ζ levels) was found
higher in invasive tissues (i.e., IDC and metastatic tissues)
when compared to non‑invasive tissues (DCIS). PKC‑ ζ
expression did not significantly change with the presence

This table was created after a review of the Catalogue of Somatic Mutations in Cancer database.

Substitution missense
Deletion frameshift, substitution
nonsense, substitution missense
Insertion frameshift, deletion
frameshift

Substitution missense, other

Substitution missense

Phosphatidylinosital‑4,5‑bisphosphate Phosphorylates certain
3q26.3
27
98.97
3‑kinase catalytic subunit α
signaling molecules				
TP53
p53
Tumor suppressor,
17p13.1
24
50.30, 25.20
		
regulates cell cycle
MED12
Mediator complex subunit 12
Initiation of transcription
Xq13
20
71.04
CDH1
E‑cadherin (Cadherin 1)
Cell adhesion
16q22.1
11
28.07, 18.42, 17.54
						
GATA3
GATA binding protein 3
Transcription factor
10p15
10
48.58, 16.60
						
PIK3CA

Highest percentage
mutation (%)
Percentage of mutated
samples tested (%)
Chromosome
location
			
Gene
Protein product
Protein function

or absence of receptors (ER and HER2) (6). Our western
blots and Chi‑squared analysis (Fig. 1A and B; Table IV)
support these findings. They performed a PKC‑ζ knockdown
mouse study and found that the depletion of PKC‑ζ leads to
an approximately 50% reduction in primary tumor growth
compared to the control within five weeks (6). Similarly, our
western blot analysis and immunohistochemistry data of IDC
and ILC (Fig. 1A‑C) suggest that PKC‑ζ might also be a novel
component in pathways that affect cancer cell invasion and
metastasis.
PKC‑ζ assists a transcription factor (NFκ B‑p65) that
downregulates targets such as E‑cadherin and ZO‑1 (6). In
addition, decreased E‑cadherin levels cause the cells to no
longer adhere to the extracellular matrix causing the cells
to migrate, invade, or metastasize (6). Moreover, Chua et al
showed that NF‑κ B induction elevated expression of Zinc
finger E‑box binding homeobox 1 and 2 (ZEB‑1 and ZEB‑2)
which ultimately repressed the E‑cadherin levels (7). In our
investigation, we could not establish a statistical relationship
between PKC‑ζ and E‑cadherin protein expression in IDC
(Fig. 2B) as per the linear regression analysis. However,
previous studies illustrated an increase in E‑cadherin levels in
PKC‑ζ knockdown MDA‑MB‑231 cells (6).
In addition, our findings showed an increased expression of PKC‑ ζ in IDC tissues when compared to other
subtypes (Fig. 1A‑C) which may be because of the difference
in pathological features of ductal and lobular tumors. Ductal
carcinomas are lined with a two‑layered stratified cuboidal
epithelium resting on the basement membrane. This cuboidal
epithelium contains tight junctions where E‑cadherins are
located and play a central role in cell‑to‑cell adhesion (18). In
contrast, lobular carcinomas vary in terms of molecular and
genetic aberrations. Lobular carcinomas are epithelial‑like,
growing individually in sheets or in a single file (4). In our
investigation, E‑cadherin levels were also compared to
the nuclear grade listed on the pathology report (Fig. 2C;
Table V), which supports the previous studies that described
a decline in E‑cadherin as a part of the epithelial to mesenchymal transition leads to metastasis (7,19).
During metastasis, directional cell movement involves five
distinct steps: leading edge membrane protrusion, adhesion
of the protrusion to the substrates, cell body translocation,
de‑adhesion of the tail from the substrate and trailing edge
retraction (20). These processes are mainly controlled by reorganization of the actin in the cell cytoskeleton which in turn
are regulated by Guanosine Triphosphatases (GTPases) (21).
Among the GTPases, RhoA, Rac1, and CDC42 are most
commonly studied because of their crucial role in actin
assembly and formation of metastatic structures of cells,
such as filopodia, lamellipodia and stress fibers (22). Rac1
and CDC42 produce localized actin polymerization at the
leading edge which pushes the membrane forward in slender
like structure known as filopodia and sheet‑like structure
known as lamellipodia that ultimately generate locomotive
force in migrating cells (23). In contrast, RhoA promotes the
assembly of contractile actomyosin filaments and acts on the
rear end of the migrating cells, inducing tail detachment (24).
Thus, Rac1 and CDC42 stimulate leading edge protrusion,
and RhoA stimulates trailing edge retraction in metastatic
cells. We found that the knockdown of PKC‑ζ by siPRKCZ

Mutation type
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Figure 4. Organization of F‑actin upon the knockdown of PKC‑ζ. MDA‑MB‑231 breast cancer cells were treated with SiTran, scrambled RNA and siPRKC‑ζ for
24 h. The cells that received no treatment were used as the control. These cells were then stained with 1X Phalloidin‑iFluor 594 and counterstained with DAPI.
Scale bar, 100 µm. Original magnification, x20. DAPI, 4',6‑diamidino‑2‑phenylindole; F‑actin, filamentous actin; PKC‑ζ, protein kinase C‑ζ.

reduced the invasion of MDA‑MB‑231 breast cancer cells by
60% (P<0.05) when compared to control (Fig. 3A and B). In
addition, there was a decreased expression of both Rac1 and
RhoA in siPRKCZ transfected MDA‑MB‑231 breast cancer
cells compared to control (Fig. 3C). Furthermore, our immunostaining analysis of F‑actin illustrated that actin filaments
were nicely organized around the cells with the inhibition of
PKC‑ζ (Fig. 4). Hence, PKC‑ζ may play an essential role in the
invasion and migration of breast cancer cells by the regulation
of RhoA and Rac1 pathways.
To conclude, our findings suggest that PKC‑ζ is found to
be most abundant in invading tissue subtypes and may be
a functional component of invasion pathways such as Rac1
and RhoA. The use of PKC‑ζ‑specific inhibitors could be
used to correlate the decrease in expression or functionality
of PKC‑ζ with the decrease in invasive behavior in breast
cancer.
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